Literature DB >> 10029095

Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.

Y Cheng1, H K Ng, M Ding, S F Zhang, J C Pang, K W Lo.   

Abstract

Glioblastoma multiforme (GBM) often displays morphological heterogeneity in that low-grade (LG) area with well-differentiated cells are commonly found adjacent to high-grade (HG) area with poorly-differentiated cells. This heterogeneity may cause difficulty in obtaining representative tumor samples. Nevertheless, the genetic composition of these cells has only been occasionally examined. In the present study, we examined 29 de novo glioblastomas in which distinct LG and HG areas of sufficient volumes could be identified. These areas were microdissected from paraffin-embedded tissues and analyzed for genetic alterations: p53 mutations and immunohistochemistry; allelic losses at 17p13.1, 9p21, and 10q23-25; and amplification of the epidermal growth factor receptor (EGFR) gene and immunohistochemistry. We also examined 14 paired astrocytic tumors, in which a primary Grade II astrocytoma progressed over a period of time to a Grade III or Grade IV tumor. Our findings showed that the LG areas of the de novo glioblastomas exhibited numerous genetic aberrations, the proportion of which was increased in the HG areas. Genetic abnormalities seen in the LG areas were conserved in the HG areas suggesting that these morphologically different cellular subsets were derived from a common transformed clone. Also, the LG areas were genetically different from Grade II astrocytomas of the paired tumor group, in spite of their morphological similarity. In particular, the LG areas had more deletions on 10q23-25 (75% vs 20%, p = 0.04), but fewer p53 mutations (24% vs 71%, p = 0.003) and less p53 protein labeling (45% vs 79%, p = 0.04). These differences suggest that LG and HG areas in de novo glioblastoma are genetically closer to each other compared with paired low- and high-grade tumors that have progressed over time. Moreover, only a small proportion (17%) of our de novo glioblastomas exhibited EGFR amplification while a high proportion (62%) showed either p53 mutations or allelic loss of 17p13.1. We speculate that some de novo GBMs with copious LG areas may constitute a separate group with rapid progression from Grade II astrocytomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029095     DOI: 10.1097/00005072-199902000-00002

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  10 in total

1.  What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia.

Authors:  Sarina Sulong; Abdul Aziz Mohamed Yusoff; Norafiza Zainuddin; Jafri Malin Abdullah; Jain George Pannatil; Hasnan Jaafar; Mohd Nizam Isa
Journal:  Malays J Med Sci       Date:  2004-01

2.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

3.  Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.

Authors:  Asha Das; Wan-Loo Tan; Jennifer Teo; Duncan R Smith
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

4.  Connection between Cell Phone use, p53 Gene Expression in Different Zones of Glioblastoma Multiforme and Survival Prognoses.

Authors:  Reza Akhavan-Sigari; Morteza Mazloum Farsi Baf; Vahid Ariabod; Veit Rohde; Saeed Rahighi
Journal:  Rare Tumors       Date:  2014-08-08

5.  IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours.

Authors:  Luyan Mu; Wanzhen Xu; Qingla Li; Haitao Ge; Hongbo Bao; Songsong Xia; Jingjing Ji; Jie Jiang; Yuwen Song; Qiang Gao
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

6.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Authors:  Okezie O Kanu; Betsy Hughes; Chunhui Di; Ningjing Lin; Jinrong Fu; Darell D Bigner; Hai Yan; Cory Adamson
Journal:  Clin Med Oncol       Date:  2009-04-08

7.  Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.

Authors:  Yu Yao; Aden Ka-Yin Chan; Zhi Yong Qin; Ling Chao Chen; Xin Zhang; Jesse Chung-Sean Pang; Hiu Ming Li; Yin Wang; Ying Mao; Ho-Keung Ng; Liang Fu Zhou
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.752

8.  Proliferation and aneusomy predict survival of young patients with astrocytoma grade II.

Authors:  P H Wessels; A H N Hopman; B Kubat; A G H Kessels; E W Hoving; M I J Ummelen; F C S Ramaekers; A Twijnstra
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

9.  High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours.

Authors:  J Hu; J C-S Pang; C Y-K Tong; B Lau; X-L Yin; W-S Poon; C-C Jiang; L-F Zhou; H-K Ng
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

10.  Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model.

Authors:  Stefano Forte; Alfredo Pagliuca; Eugenia T Maniscalchi; Rosario Gulino; Giovanna Calabrese; Lucia Ricci-Vitiani; Roberto Pallini; Michele Signore; Rosalba Parenti; Ruggero De Maria; Massimo Gulisano
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.